VivoSeq
Immunology

Pemphigus

24

Pipeline Programs↗

6

Active Trials↗

13

Companies Involved↗

Pemphigus is an emerging landscape with 24 programs across 13 companies. The most active players are Prism Pharmaceuticals, Sanofi, AstraZeneca. 1 therapy is approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

6/100

Mech. Concentration

22/100

Completion Rate

67/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Prism Pharmaceuticals

1 program

Phase 1Sanofi logo

Sanofi

2 programs

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2Novo Nordisk logo

Novo Nordisk

1 program

Phase 2K

Keymed Biosciences Co.Ltd

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

78%

Small molecule

18 of 23 classified programs — the dominant modality here.

22%ALL OTHERSMonoclonal antibody417%Protein / enzyme14%

Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 25 pipeline programs.

Analysis

Trial Status

26

clinical trials

Completed12 · 46%
Terminated6 · 23%
Recruiting3 · 12%
Not yet recruiting2 · 8%
Unknown status2 · 8%
Active, not recruiting1 · 4%

Clinical Trials

Trial Activity

26 trials

A Clinical Study of B007 in the Treatment of Pemphigus.
Recruiting·SShanghai Jiaolian Drug Research and Development Co., Ltd·Phase 2/3·NCT06454357·132 enrolled
Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus
Recruiting·UUniversity Hospital, Rouen·Phase 4·NCT05898308·133 enrolled
ONO-4059 Study in Patients With Steroid-resistant Pemphigus
Recruiting·Ono Pharmaceutical Co. Ltd logoOno Pharmaceutical Co. Ltd·Phase 3·NCT06696716·34 enrolled
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus
Active, not recruiting·TThe University of Hong Kong·Phase 2·NCT04400994·20 enrolled
A Single-center Study of CM313 in Patients With Pemphigus
Not yet recruiting·SSichuan Provincial People's Hospital·N/A·NCT06904040·20 enrolled
A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.
Not yet recruiting·—·Phase 1/2·NCT06663943·100 enrolled
Effect of Topical Insulin on Healing Rate of Pemphigus Lesions
Completed·—·Phase 2·NCT07461103·20 enrolled
Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab
Completed·UUniversity Hospital, Rouen·Phase 3·NCT01299857·22 enrolled
Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus
Completed·JJohns Hopkins University·Phase 2·NCT00010413·35 enrolled
Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid.
Completed·UUniversity Hospital, Limoges·Phase 3·NCT02993133·53 enrolled
Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" Trial
Completed·UUniversity Hospital, Rouen·Phase 3·NCT03790293·80 enrolled
Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus
Completed·UUniversity Hospital, Rouen·N/A·NCT00213421·330 enrolled
A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus
Completed·Argenx logoArgenx·Phase 2·NCT03334058·34 enrolled
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
Completed·UUniversity of Luebeck·Phase 2·NCT00656656·23 enrolled
Effect of Anti CD20 in Pemphigus Desease
Completed·UUniversity Hospital, Rouen·Phase 2/3·NCT00213512·22 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)